Currently, various MDM2 antagonists have been developed to stabilize the p53 protein and inhibit tumor progression by disrupting the protein–protein interaction between MDM2 and p53 or by targeting MDM2 for degradation. This evidence concerns the gene TP53 and neoplasm.